Joonmi Oh
Overview
Explore the profile of Joonmi Oh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
636
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schwarz A, Sundell K, Charil A, Case M, Jaeger R, Scott D, et al.
Alzheimers Dement (N Y)
. 2019 Aug;
5:328-337.
PMID: 31388559
Introduction: Solanezumab is a humanized monoclonal antibody that preferentially binds to soluble amyloid β and promotes its clearance from the brain in preclinical studies. The objective of this study was...
2.
Carlson C, Siemers E, Hake A, Case M, Hayduk R, Suhy J, et al.
Alzheimers Dement (Amst)
. 2016 May;
2:75-85.
PMID: 27239538
Introduction: Solanezumab, a humanized monoclonal antibody that binds soluble amyloid beta peptide, is being developed for treatment of Alzheimer's disease (AD). Methods: Patients (n = 2042) with mild and moderate...
3.
Pai A, Sporring J, Darkner S, Dam E, Lillholm M, Jorgensen D, et al.
J Med Imaging (Bellingham)
. 2016 Mar;
3(1):014005.
PMID: 27014717
Obtaining regional volume changes from a deformation field is more precise when using simplex counting (SC) compared with Jacobian integration (JI) due to the numerics involved in the latter. Although...
4.
Sevigny J, Suhy J, Chiao P, Chen T, Klein G, Purcell D, et al.
Alzheimer Dis Assoc Disord
. 2016 Feb;
30(1):1-7.
PMID: 26885819
Amyloid positron emission tomography (PET) imaging is being investigated as a screening tool to identify amyloid-positive patients as an enrichment strategy for Alzheimer disease (AD) clinical trial enrollment. In a...
5.
Llufriu S, Kornak J, Ratiney H, Oh J, Brenneman D, Cree B, et al.
JAMA Neurol
. 2014 May;
71(7):840-7.
PMID: 24839987
Importance: Predicting disease evolution is becoming essential for optimizing treatment decision making in multiple sclerosis (MS). Multiple sclerosis pathologic damage typically includes demyelination, neuro-axonal loss, and astrogliosis. Objective: To evaluate...
6.
Aisen P, Gauthier S, Ferris S, Saumier D, Haine D, Garceau D, et al.
Arch Med Sci
. 2012 Feb;
7(1):102-11.
PMID: 22291741
Introduction: The aim of the study was to assess the clinical efficacy, safety, and disease-modification effects of tramiprosate (homotaurine, ALZHEMED(TM)) in mild-to-moderate Alzheimer's disease (AD). Material And Methods: Double-blind, placebo-controlled,...
7.
Carlson C, Estergard W, Oh J, Suhy J, Jack Jr C, Siemers E, et al.
Alzheimers Dement
. 2011 Jul;
7(4):396-401.
PMID: 21784350
Background: Cerebral vasogenic edema (VE) has been reported to occur during antiamyloid immunotherapy. VE may be associated with central nervous system pathology with blood-brain barrier disruptions; however, less is known...
8.
Oh J, Han E, Lee M, Nelson S, Pelletier D
J Neuroimaging
. 2007 Apr;
17(2):156-63.
PMID: 17441837
Purpose: To evaluate a multislice nonlinearly-spaced 12-echo imaging sequence at 3T covering the supratentorial brain for the quantification of myelin water fraction (MWF) in multiple sclerosis (MS) patients. Methods: Eighty-nine...
9.
Oh J, Han E, Pelletier D, Nelson S
Magn Reson Imaging
. 2006 Jan;
24(1):33-43.
PMID: 16410176
The objective of this study was to implement a clinically relevant multi-slice multi-echo imaging sequence in order to quantify multi-component T2 relaxation times for normal volunteers at both 1.5 and...
10.
Oh J, Cha S, Aiken A, Han E, Crane J, Stainsby J, et al.
J Magn Reson Imaging
. 2005 May;
21(6):701-8.
PMID: 15906339
Purpose: To investigate the potential value and relationship of in vivo quantification of apparent diffusion coefficients (ADCs) and T2 relaxation times for characterizing brain tumor cellularity and tumor-related edema. Materials...